SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guidant (GDT)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lance Bredvold who wrote (230)2/16/2006 9:04:27 AM
From: Allegoria   of 235
 
Let's lay out the facts as they stand today.
As some have suggested, this is a very attractive arb. to play, especially if you BOT at yesterdays price of $75.00/GDT.
From my research I see little risk in returning $80 on a $75 purchase, in approx. 60 days.

The numbers:
Each share of GDT will be exchanged for $42.00 in cash and $38.00 in BSX.
IF BSX is less than......$22.62, GDT receives 1.6799/BSX
IF BSX is greater than $28.86, GDT receives 1.3167/BSX

As of Jan. 17th, the collar was significantly expanded: (noteably the timing of the collar which will protect the GDT'ers.)

Expanded collar through closing -- To provide Guidant shareholders with additional certainty of value, Boston Scientific has adjusted the bottom of the collar around the stock portion of the merger consideration by $1 from $23.62 to $22.62, which is approximately 10 percent below the closing price of Boston Scientific stock on Friday, January 13, 2006. The top of the collar remains $28.86. In addition, Boston Scientific has moved the timing of the collar from just prior to the date of the Guidant shareholders meeting until just prior to the closing date.

Interest payments -- If the closing of the transaction does not occur by March 31, 2006, the $80 per share price would be increased by $0.0132 in cash for each day between April 1, 2006 and the date of closing (representing an annual interest rate of 6 percent).

Boston Scientific expects to complete the transaction by the end of the first quarter of 2006. Finally I would note that there are no financing conditions and as of Jan. 17th, 30% of BSX holders have voted in favor of the merger.
Examining the primary risks reveals little chance that BSX would voluntarially

Insider buying at BSX is very positive as well:
fool.com

Examine the risks of the deal not going through:
Most analyst agree there is little chance that BSX would voluntarily walk from the deal.
Regulatory approval is nearly certain given the ABT purchase/ BSX’s divesture of Guidant's vascular intervention and endovascular businesses.

For what will likely be a 60 day hold and relatively little risk, it's a very sweet return.

Good luck,
Eric
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext